In contrast, a Phase 2 clinical trial (RESCUE) demonstrated that targeting IL‐6 ligand using ziltivekimab inhibited atherosclerosis progress by reducing high‐sensitivity C‐reactive protein (CRP), fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein(a), independent of TC/HDL‐C ratio.8 This evidence concerns the gene CRP and atherosclerosis.